Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2010

View Archived Issues

GlaxoSmithKline updates progress of second quarter 2010

Ortho-McNeil-Janssen Pharma claims new gamma-secretase modulators

SAR-106881, an FGFR agonist derived from FGFR antagonists

New SGLT-2 inhibitor CSG-452 is selected as clinical candidate

Scientists present preclinical data on new HCV NS4A antagonists at ACS meeting

Enrollment complete in phase IIb trial of PEG-interferon lambda in hepatitis C

Somaxon and Procter & Gamble to copromote Silenor for insomnia

Omni Bio Pharm and UCD to begin preclinical study of AAT in influenza

Neuralstem files IND for phase I trial of stem cells in chronic spinal cord injury

Impax's phase III trial of IPX-066 in PD completes enrollment

Aoxing receives approval in China for buprenorphine/naloxone clinical trial

Avi BioPharma reports preclinical data on AVI-7100 for H1N1 influenza

FDA approves brand name Veletri for epoprostenol injection therapy for PAH

Pharmasset begins phase IIb trial of PSI-7977 in chronic hepatitis C

New hepatocyte growth factor receptor inhibitors claimed by sanofi-aventis

Cellceutix moves toward human trials of Kevetrin for drug-resistant cancer

Exelixis discovers new ceramide glucosyltransferase inhibitors

Rigel Pharmaceuticals presents new inhibitors of protein kinase C

New adenosylhomocysteinase inhibitors show preclinical potential to treat AD

FDA grants orphan status to LFB-R603 for chronic lymphocytic leukemia

Novartis purchases majority interest in Alcon from Nestle

FDA accepts pivotal phase III data for acyclovir Lauriad NDA

Pfizer discloses new inhibitors of diacylglycerol O-acyltransferase 2

Daiichi Sankyo launches Tribenzor in U.S.

Scientists generate functional dopaminergic neurons from human iPSCs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...